Skip to Content

33 Results Found

  • Article
  • Open Access
715 Views
14 Pages

Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period

  • Stephanie H. Read,
  • Lucie Kutikova,
  • Gaelle Gusto,
  • Raissa Kapnang and ,
  • Nadia Quignot,
  • Artak Khachatryan,
  • Clotilde El Guerche-Séblain,
  • Vincent Petit,
  • Jonathan Fix and
  • Odile Launay
  • + 7 authors+ 2 authors

9 September 2026

Background/Objectives: The Novavax COVID-19 vaccine (Nuvaxovid™) was authorized in France in December 2021, assisting in ending the global pandemic and providing an alternative to other COVID-19 vaccines. Understanding Nuvaxovid recipients&rsqu...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Article
  • Open Access
16 Citations
4,397 Views
15 Pages

Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations

  • Sandra M. Salter,
  • Dani Li,
  • Kevin Trentino,
  • Lisa Nissen and ,
  • Kenneth Lee,
  • Karin Orlemann,
  • Ian Peters,
  • Kevin Murray,
  • Alan Leeb and
  • Lucy Deng
  • + 5 authors+ 0 author

25 November 2022

Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisat...

(This article belongs to the Special Issue Safety and Autoimmune Response to SARS-CoV-2 Vaccination)
  • Article
  • Open Access
5 Citations
10,235 Views
12 Pages

Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia

  • Renee Reynolds,
  • Evelyn Tay,
  • Michael Dymock,
  • Lucy Deng and ,
  • Catherine Glover,
  • Laura K. Lopez,
  • Yuanfei Anny Huang,
  • Patrick Cashman,
  • Alan Leeb and
  • Kristine Macartney
  • + 8 authors+ 3 authors

27 August 2024

Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxo...

(This article belongs to the Section Vaccine Advancement, Efficacy and Safety)
  • Article
  • Open Access
14 Citations
3,680 Views
11 Pages

Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity

  • Zhaohui Cai,
  • Raj Kalkeri,
  • Mi Wang,
  • Benjamin Haner and ,
  • Dominic Dent,
  • Bahar Osman,
  • Paul Skonieczny,
  • Jeremy Ross,
  • Sheau-Line Feng and
  • Joyce S. Plested
  • + 8 authors+ 3 authors

The evaluation of coronavirus disease 2019 (COVID-19) vaccine immunogenicity remains essential as the severe acute respiratory syncytial virus 2 (SARS-CoV-2) pandemic continues to evolve and as additional variants emerge. Neutralizing antibodies are...

(This article belongs to the Special Issue SARS-CoV-2/COVID-19: Infection Models, Therapeutics and Vaccines, Second Edition)
  • Article
  • Open Access
7 Citations
2,974 Views
10 Pages

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates

  • Cheryl A. Triplett,
  • Nancy A. Niemuth,
  • Christopher Cirimotich,
  • Gabriel Meister and ,
  • Mimi Guebre-Xabier,
  • Nita Patel,
  • Mike Massare,
  • Greg Glenn,
  • Gale Smith and
  • Ricardo Carrion
  • + 7 authors+ 2 authors

18 August 2022

Non-human primate (NHP) efficacy data for several Ebola virus (EBOV) vaccine candidates exist, but definitive correlates of protection (CoP) have not been demonstrated, although antibodies to the filovirus glycoprotein (GP) antigen and other immunolo...

(This article belongs to the Special Issue Vaccine Development Needs for Marburg Virus and Sudan Ebolavirus: Leveraging Lessons Learned from the Zaire Ebolavirus)
  • Article
  • Open Access
5 Citations
5,266 Views
20 Pages

A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine

  • Timothy S. Vincent,
  • Mingzhu Zhu,
  • Anand Parekh,
  • Urvashi Patel and ,
  • Shane Cloney-Clark,
  • Andrew Klindworth,
  • David Silva,
  • Andrew Gorinson,
  • Karlee Miranda and
  • Joyce S. Plested
  • + 13 authors+ 8 authors

Currently available seasonal influenza vaccines confer variable protection due to antigenic changes resulting from the accumulation of diverse mutations. The analysis of new seasonal influenza vaccines is challenging in part due to the limitations of...

(This article belongs to the Section Medical Microbiology)
  • Review
  • Open Access
16 Citations
6,582 Views
17 Pages

An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines

  • Suhaila A. Al-Sheboul,
  • Brent Brown,
  • Yasemin Shboul,
  • Ingo Fricke and ,
  • Chinua Imarogbe and
  • Karem H. Alzoubi
  • + 1 author+ 0 author

26 December 2022

The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive-sense single-stranded RNA (ssRNA) structure. It is in the order Nidovirales, subord...

(This article belongs to the Section Vaccines, Clinical Advancement, and Associated Immunology)
  • Systematic Review
  • Open Access
2 Citations
5,975 Views
61 Pages

COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis

  • Angel Justiz-Vaillant,
  • Kimberly Roopnarine,
  • Shaundell Solomon,
  • Alyssa Phillips and ,
  • Solange Sandy,
  • Alyssa Subero,
  • Sarah Seepersad,
  • Nicholas Span,
  • Phalmanie Ramnath and
  • Patrick Eberechi Akpaka
  • + 32 authors+ 27 authors

This systematic review evaluated the effectiveness and side effects of various COVID-19 vaccines, with a focus on Trinidad and Tobago. The Pfizer-BioNTech and Moderna vaccines demonstrated the highest efficacy, particularly against COVID-19 variants,...

(This article belongs to the Section Virology)
  • Article
  • Open Access
15 Citations
2,929 Views
18 Pages

A Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine Immunogenicity Using an Established Correlate of Protection

  • Mingzhu Zhu,
  • Shane Cloney-Clark,
  • Sheau-line Feng,
  • Anand Parekh and ,
  • Drew Gorinson,
  • David Silva,
  • Paul Skonieczny,
  • Adjele Wilson,
  • Raj Kalkeri and
  • Joyce S. Plested
  • + 9 authors+ 4 authors

As the COVID-19 pandemic continues, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge. Immunogenicity evaluation of vaccines and identification of correlates of protection for vaccine effectiveness is critica...

(This article belongs to the Special Issue SARS-CoV-2/COVID-19: Infection Models, Therapeutics and Vaccines)
  • Article
  • Open Access
8 Citations
2,963 Views
14 Pages

Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

  • Joyce S. Plested,
  • Mingzhu Zhu,
  • Shane Cloney-Clark,
  • Edmond Massuda and ,
  • Urvashi Patel,
  • Andrew Klindworth,
  • Michael J. Massare,
  • Rongman Cai,
  • Louis Fries and
  • Raj Kalkeri
  • + 6 authors+ 1 author

Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show immune evasion of vaccine-derived immunity, highlighting the need for better clinical immunogenicity biomarkers. To address this need, an enzyme-linked immunosorbe...

(This article belongs to the Special Issue SARS-CoV-2/COVID-19: Infection Models, Therapeutics and Vaccines)
  • Article
  • Open Access
993 Views
12 Pages

Validation of a Mucosal IgA Assay for SARS-CoV-2

  • Mingzhu Zhu,
  • Edmond Massuda,
  • Shane Cloney-Clark,
  • Urvashi Patel and ,
  • Anand Parekh,
  • Andrew Gorinson,
  • Andrew Klindworth,
  • Ali Ahmadi,
  • Miranda R. Cai and
  • Joyce S. Plested
  • + 7 authors+ 2 authors

Mucosal immunity, including antibodies like immunoglobulin A (IgA), function as the body’s first line of defense in the respiratory tract, particularly against viruses. An anti-rS protein IgA enzyme-linked immunosorbent assay (ELISA) was develo...

(This article belongs to the Section Molecular Microbiology and Immunology)
  • Article
  • Open Access
1,098 Views
15 Pages

Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2 Omicron JN.1 and LP.8.1 Subvariant Lineage Strains with Homologous and Heterologous Matched Sera in Clinically Relevant Samples

  • Zhaohui Cai,
  • Raj Kalkeri,
  • Benjamin Haner,
  • Mi Wang and ,
  • Paul Skonieczny,
  • Bahar Osman,
  • Dominic Dent,
  • David Silva,
  • Kevin Auerbach and
  • Joyce S. Plested
  • + 10 authors+ 5 authors

The pseudovirus neutralization (PNT) assay is an established high-throughput, robust, and efficient BSL-2 method for detecting neutralizing antibodies (NAbs) against SARS-CoV-2 with the correlates of protection previously established for the ancestra...

(This article belongs to the Section Virology)
  • Article
  • Open Access
15 Citations
7,463 Views
14 Pages

A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2–Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation

  • Zhaohui Cai,
  • Raj Kalkeri,
  • Mingzhu Zhu,
  • Shane Cloney-Clark and ,
  • Benjamin Haner,
  • Mi Wang,
  • Bahar Osman,
  • Dominic Dent,
  • Sheau-Line Feng and
  • Joyce S. Plested
  • + 7 authors+ 2 authors

Neutralizing antibody responses from COVID-19 vaccines are pivotal in conferring protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Effective COVID-19 vaccines and assays measuring neutralizing antibodies against emergin...

(This article belongs to the Section Virology)
  • Article
  • Open Access
36 Citations
11,106 Views
17 Pages

Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA

  • Alyse D. Portnoff,
  • Nita Patel,
  • Michael J. Massare,
  • Haixia Zhou and ,
  • Jing-Hui Tian,
  • Bin Zhou,
  • Vivek Shinde,
  • Gregory M. Glenn and
  • Gale Smith
  • + 4 authors+ 0 author

22 February 2020

Influenza vaccine effectiveness varies annually due to the fast evolving seasonal influenza A(H3N2) strain and egg-derived mutations—both of which can cause a mismatch between the vaccine and circulating strains. To address these limitations, w...

(This article belongs to the Section Influenza Virus Vaccines)
  • Article
  • Open Access
3 Citations
5,387 Views
21 Pages

Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model

  • Clive Pritchard,
  • Lucie Kutikova,
  • Richard Pitman,
  • Kira Zhi Hua Lai and ,
  • Hadi Beyhaghi,
  • IIana Gibbons,
  • Amanda Erbe,
  • Marija Živković-Gojović,
  • Catherine Cosgrove and
  • David Salisbury
  • + 6 authors+ 1 author

14 February 2025

Background/Objectives: Vaccination against SARS-CoV-2 remains a key measure to control COVID-19. Nuvaxovid, a recombinant Matrix-M–adjuvanted protein-based vaccine, showed similar efficacy to mRNA vaccines in clinical trials and real-world stud...

  • Article
  • Open Access
11 Citations
5,593 Views
20 Pages

Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study

  • Matthew D. Rousculp,
  • Kelly Hollis,
  • Ryan Ziemiecki,
  • Dawn Odom and ,
  • Anthony M. Marchese,
  • Mitra Montazeri,
  • Shardul Odak,
  • Laurin Jackson,
  • Angela Miller and
  • Seth Toback
  • + 5 authors+ 0 author

13 January 2024

As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool to reduce the COVID-19 burden. Vaccine reactogenicity and the impact on work productivity/daily activities are recognized as contributing factors to vaccine hesitancy. To...

  • Article
  • Open Access
11 Citations
6,334 Views
14 Pages

Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines

  • Matthew D. Rousculp,
  • Kelly Hollis,
  • Ryan Ziemiecki,
  • Dawn Odom and ,
  • Anthony M. Marchese,
  • Mitra Montazeri,
  • Shardul Odak,
  • Laurin Jackson,
  • Hadi Beyhaghi and
  • Seth Toback
  • + 5 authors+ 0 author

19 July 2024

Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational 2019nCoV-...

(This article belongs to the Special Issue Knowledge, Attitudes, Beliefs and Hesitancy towards COVID-19 Vaccination and Booster Doses)
  • Article
  • Open Access
25 Citations
8,454 Views
20 Pages

Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity

  • Nita Patel,
  • Jing-Hui Tian,
  • Rhonda Flores,
  • Kelsey Jacobson and ,
  • Michelle Walker,
  • Alyse Portnoff,
  • Mimi Gueber-Xabier,
  • Michael J. Massare,
  • Greg Glenn and
  • Gale Smith
  • + 6 authors+ 1 author

14 October 2020

Human respiratory syncytial virus (RSV) is a cause of lower respiratory tract infection in infants, young children, and older adults. There is no licensed vaccine and prophylactic treatment options are limited. The RSV fusion (F) glycoprotein is a ta...

(This article belongs to the Special Issue Evaluation of Vaccine Immunogenicity)
  • Article
  • Open Access
18 Citations
7,991 Views
16 Pages

1 June 2022

Chicken serum albumin, i.e., hen egg alpha-livetin, is a recognized food allergen in chicken meat and hen eggs. Currently, there is no immunoassay available for its detection from food matrices. The characterization of chicken serum albumin-specific...

(This article belongs to the Special Issue Rapid Analysis Technology for Food Quality and Safety)
  • Article
  • Open Access
5 Citations
4,325 Views
16 Pages

Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States

  • Kyle Paret,
  • Hadi Beyhaghi,
  • William L. Herring,
  • Josephine Mauskopf and ,
  • Lesley G. Shane and
  • Matthew D. Rousculp
  • + 1 author+ 0 author

12 January 2024

Policymakers in the United States (US) recommend coronavirus disease 2019 (COVID-19) vaccination with a monovalent 2023–2024 vaccine formulation based on the Omicron XBB.1.5 variant. We estimated the potential US population-level health and eco...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Review
  • Open Access
7 Citations
4,090 Views
14 Pages

20 March 2023

COVID-19 is an infectious disease caused by the novel coronavirus (SARS-CoV-2) that first appeared in late 2019 and has since spread across the world. It is characterized by symptoms such as fever, cough, and shortness of breath and can lead to death...

(This article belongs to the Special Issue The Therapeutic Applications of Extracellular Vesicles)
  • Brief Report
  • Open Access
3 Citations
7,578 Views
10 Pages

Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany

  • Lucie Kutikova,
  • James T. Brash,
  • Kawitha Helme,
  • Jack Brewster and ,
  • Milou Brand,
  • Atif Adam,
  • Sarah Seager,
  • Karel Kostev and
  • Jörg Schelling
  • + 4 authors+ 0 author

6 April 2024

Real-world evidence supports SARS-CoV-2 vaccination strategies during the COVID-19 pandemic. This real-world retrospective study utilized the German Disease Analyzer database to characterize recipients of NVX-CoV2373 and explore vaccination outcomes....

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Article
  • Open Access
12 Citations
3,338 Views
16 Pages

Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity

  • Min Z. Levine,
  • Crystal Holiday,
  • Yaohui Bai,
  • Weimin Zhong and ,
  • Feng Liu,
  • Stacie Jefferson,
  • F. Liaini Gross,
  • Wen-pin Tzeng,
  • Louis Fries and
  • Terrence Tumpey
  • + 15 authors+ 10 authors

1 November 2022

Influenza A(H7N9) viruses remain as a high pandemic threat. The continued evolution of the A(H7N9) viruses poses major challenges in pandemic preparedness strategies through vaccination. We assessed the breadth of the heterologous neutralizing antibo...

(This article belongs to the Special Issue Technologies for Influenza Vaccines that Provide Increased Speed, Efficacy and Ease of Administration)
  • Review
  • Open Access
31 Citations
8,092 Views
23 Pages

The Magic Staff: A Comprehensive Overview of Baculovirus-Based Technologies Applied to Human and Animal Health

  • Matías L. Pidre,
  • Paula N. Arrías,
  • Leslie C. Amorós Morales and
  • Víctor Romanowski

28 December 2022

Baculoviruses are enveloped, insect-specific viruses with large double-stranded DNA genomes. Among all the baculovirus species, Autographa californica multiple nucleopolyhedrovirus (AcMNPV) is the most studied. Due to its characteristics regardi...

(This article belongs to the Section Invertebrate Viruses)
  • Article
  • Open Access
25 Citations
10,901 Views
16 Pages

N-1 Perfusion Platform Development Using a Capacitance Probe for Biomanufacturing

  • Emily S. C. Rittershaus,
  • Matthew S. Rehmann,
  • Jianlin Xu,
  • Qin He and ,
  • Charles Hill,
  • Jeffrey Swanberg,
  • Michael C. Borys,
  • Zheng-Jian Li and
  • Anurag Khetan
  • + 4 authors+ 0 author

Fed-batch process intensification with a significantly shorter culture duration or higher titer for monoclonal antibody (mAb) production by Chinese hamster ovary (CHO) cells can be achieved by implementing perfusion operation at the N-1 stage for bio...

(This article belongs to the Topic Bioreactors: Control, Optimization and Applications)
  • Article
  • Open Access
1 Citations
3,183 Views
13 Pages

17 September 2024

Background/Objectives: This study aimed to assess the reactogenicity and immunogenicity of various SARS-CoV-2 vaccines and compare their protective effects against COVID-19 among healthcare workers (HCWs) during the Omicron outbreak in Taiwan. Method...

(This article belongs to the Special Issue Efficacy, Immunogenicity and Safety of COVID-19 Vaccines and COVID-19 Vaccination Strategies)
  • Article
  • Open Access
3 Citations
2,923 Views
14 Pages

Analysis of Allergy and Hypersensitivity Reactions to COVID-19 Vaccines According to the EudraVigilance Database

  • Jan Romantowski,
  • Wojciech Nazar,
  • Kinga Bojahr,
  • Iwona Popiołek and
  • Marek Niedoszytko

31 May 2024

Background: The coronavirus disease 2019 (COVID-19) pandemic presented a new challenge in modern medicine: the development of vaccines was followed by massive population vaccinations. A few reports on post-vaccination allergic reactions have made pat...

(This article belongs to the Section Medical Research)
  • Review
  • Open Access
49 Citations
7,696 Views
20 Pages

Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines

  • Acharya Balkrishna,
  • Vedpriya Arya,
  • Akansha Rohela,
  • Ashwani Kumar and ,
  • Rachna Verma,
  • Dinesh Kumar,
  • Eugenie Nepovimova,
  • Kamil Kuca,
  • Naveen Thakur and
  • Pankaj Kumar
  • + 6 authors+ 1 author

4 October 2021

SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat...

(This article belongs to the Special Issue Virus-Like Particle and Nano-Particle Vaccines 2.0)
  • Article
  • Open Access
9 Citations
4,165 Views
15 Pages

Immediate Adverse Events Following COVID-19 Vaccination in Australian Pharmacies: A Retrospective Review

  • Alexander T. Gallo,
  • Lisa Scanlon,
  • Jade Clifford,
  • Lawson Patten-Williams and ,
  • Lachlan Tweedie,
  • Dani Li and
  • Sandra M. Salter
  • + 2 authors+ 0 author

29 November 2022

Background: Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax), and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine the type and manageme...

(This article belongs to the Special Issue Adverse Events of COVID-19 Vaccines)
  • Article
  • Open Access
8 Citations
8,187 Views
16 Pages

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning

  • Qin He,
  • Matthew S. Rehmann,
  • Jun Tian,
  • Jianlin Xu and ,
  • Luzmary Sabino,
  • Erik Vandermark,
  • Ziev Basson,
  • Iris Po,
  • Kathleen Bierilo and
  • Zheng-Jian Li
  • + 11 authors+ 6 authors

Improving productivity to reduce the cost of biologics manufacturing and ensure that therapeutics can reach more patients remains a major challenge faced by the biopharmaceutical industry. Chinese hamster ovary (CHO) cell lines are commonly prepared...

(This article belongs to the Topic Bioreactors: Control, Optimization and Applications)
  • Article
  • Open Access
4 Citations
6,393 Views
12 Pages

Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study

  • Francesca Futura Bernardi,
  • Annamaria Mascolo,
  • Marina Sarno,
  • Nicolina Capoluongo and ,
  • Ugo Trama,
  • Rosanna Ruggiero,
  • Liberata Sportiello,
  • Giovanni Maria Fusco,
  • Massimo Bisogno and
  • Alessandro Perrella
  • + 9 authors+ 4 authors

10 October 2023

Introduction: Real-world safety studies can provide important evidence on the thromboembolic risk associated with COVID-19 vaccines, considering that millions of people have been already vaccinated against COVID-19. In this study, we aimed to estimat...

(This article belongs to the Special Issue Epidemiology, Vaccinology and Surveillance of COVID-19)
  • Article
  • Open Access
110 Citations
17,023 Views
13 Pages

The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland

  • Piotr Rzymski,
  • Joanna Zeyland,
  • Barbara Poniedziałek,
  • Ilona Małecka and
  • Jacek Wysocki

14 April 2021

Vaccine hesitancy is a major threat to the success of COVID-19 vaccination programs. The present cross-sectional online survey of adult Poles (n = 1020) expressing a willingness to receive the COVID-19 vaccine was conducted between February and March...

(This article belongs to the Special Issue Health Technology Assessment (HTA) of New vaccines and New Target Groups and Impact Evaluation and Effectiveness of Current Vaccination Strategies)
  • Article
  • Open Access
1 Citations
1,671 Views
15 Pages

Precautionary Health Behaviours as Potential Confounders in COVID-19 Vaccine Effectiveness Studies

  • Chloé Wyndham-Thomas,
  • Leonie de Munter,
  • Kok Yew Ngew,
  • Sanskruti Gaikwad and ,
  • Konstantina Chatzikonstantinidou,
  • Antonio Carmona,
  • Charlotte Martin,
  • Gerrit Luit ten Kate,
  • Nicolas Praet and
  • Kaatje Bollaerts
  • + 7 authors+ 2 authors

12 October 2025

Background/Objectives: Precautionary health behaviours (PHBs), such as hand-washing or self-isolation, are non-pharmaceutical interventions used to reduce SARS-CoV-2 transmission. We investigated the potential confounding by PHBs of COVID-19 vaccine...

(This article belongs to the Special Issue Advance Public Health Through Vaccination)